Genmab — September 2019
-
Although no objective tumor responses were observed, 11 patients (73%) had stable disease with median treatment duration of 24 weeks (range, 4–54 weeks). Serum IL-8 was significantly reduced on day 3 of HuMax-IL8 treatment compared to baseline (p = 0.0004), with reductions in IL-8 seen at all dose levels.
-
Tumor respons er en ting. Det vigtigste er, at IL-8 signifikant reduceres og patienterne samtidigt stabiliseres i sygdomsstadier samtidig med en god bivirkningsprofil.
-
Det giver god mening med HuMax-IL8 til at undertrykke serum IL8 og andre stoffer til angribe tumorerne fra forskellige vinkler.
-
Jeg besøgte for nyligt Cantargia, som også arbejder med undertrykkelse af interleukiner i forbindelse med cancer og inflammation. Deres primære target er IL-1 i forbindelse med to forskellige lungekræfttyper. Besøget gav mig et god forståelse af potentialet i den type behandlinger.
-
Groft sagt betyder forhøjet interleukin forhøjet inflammation som igen betyder vækst i svulster og metastaseudvikling.
-
det er lidt en sløj fejring af en 1st line godkendelse, vi er vidne til i dag
-
ja, det er blevet andre tider for GEN aktien
-
det ser ud til at blokken stadig forhindrer at vi kommer over 1400
-
1.400 i slut.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind